5.60
-0.17(-2.95%)
Currency In USD
| Previous Close | 5.77 |
| Open | 5.72 |
| Day High | 5.88 |
| Day Low | 5.58 |
| 52-Week High | 23.48 |
| 52-Week Low | 5.41 |
| Volume | 1.46M |
| Average Volume | 1.37M |
| Market Cap | 484.82M |
| PE | -2.68 |
| EPS | -2.09 |
| Moving Average 50 Days | 6.16 |
| Moving Average 200 Days | 10.18 |
| Change | -0.17 |
If you invested $1000 in Kura Oncology, Inc. (KURA) since IPO date, it would be worth $373.33 as of July 02, 2025 at a share price of $5.6. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $339.6 as of July 02, 2025 at a share price of $5.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
GlobeNewswire Inc.
Jun 12, 2025 11:30 AM GMT
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – 93% (41/44) and 89% (24/27) CRc observed in NPM1-m
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 10:00 PM GMT
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, o
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
GlobeNewswire Inc.
Jun 01, 2025 11:00 PM GMT
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of